Hepatic: Bilirubin ?. times upper limits of normal (ULN), alanine aminotransferase (ALT) ? . times ULN. ALT/AST ? times ULN Has liver fibrosis either determined by imaging or laboratory testing (i.e. total serum bilirubin > . times ULN, AST and ALT > . times ULN, INR > . times ULN, albumin < . mg/dl) ALT or AST greater than . times the ULN in the presence of known hepatic metastases Alanine aminotransferase (ALT) < . times upper limit of normal (ULN) or ALT < . times ULN in the presence of liver metastases AST (SGOT) and ALT (SGPT) ? times institutional ULN; if liver metastases are present, then ? times ULN is allowed. Aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) =< times ULN (within days prior to registration) PRIOR TO INFUSION OF ATLCAR.CD CELLS: AST ? times ULN ALT/AST ? . times ULN, or < times ULN for subjects with liver metastases AST or ALT > times ULN, AST or ALT > times ULN for patients with liver metastases. ALT/AST ? . times ULN, or < times ULN for subjects with liver metastases transaminases (AST or ALT) levels, times greater than the ULN, except if related to ALL/LBL, Alanine and aspartate transaminases (ALT and AST) =< . times the ULN (=< x ULN for patients with liver involvement) AST and ALT < times ULN; ALP < times ULN; Bilirubin ? . times ULN; Creatinine ? . times ULN and eGFR ? . ALT and AST >. times the ULN if no liver involvement or > times the ULN with liver involvement. Alanine aminotransferase (ALT) =< . times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT =< . times ULN is acceptable Adequate liver function defined by a bilirubin value ? times the upper limit of normal (ULN), and transaminases (AST and ALT) values ?. times ULN ALT/AST ? . times ULN, or < times ULN for subjects with liver metastases Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) =< . times the ULN except in patients with hepatic metastases for whom AST and ALT must be < . times the ULN Have serum aspartate aminotransferase (AST) > times upper limit of normal (ULN) at screening, or serum alanine aminotransferase (ALT) > times ULN at screening, or total bilirubin >= . x ULN at screening (except for documented Gilbert's syndrome), by local or central lab. Subjects with biopsy confirmed CMV hepatitis will not be excluded from study participation despite AST or ALT > times ULN at screening. At least one of the following clinical, laboratory, or imaging parameters:\r\n* Mild or moderate ascites\r\n* Serum bilirubin >= mg/dl but less than mg/dl\r\n* Aspartate aminotransferase (AST) > times upper limit of normal (ULN) but =< times ULN\r\n* Alanine aminotransferase (ALT) > times upper limit of normal (ULN) but =< times ULN\r\n* International normalized ratio for prothrombin time (INR) >. but =< .\r\n* Bland portal vein thrombosis (branch or main)\r\n* Functioning transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shunt PHASE II: AST (SGOT) and ALT (SGPT) =< times institutional ULN (=< times if LFT elevations due to known liver metastases) Dysfunction of liver (ALT/AST > times normal value, or bilirubin > times normal value), or of renal function (creatinine clearance = times the ULN Inadequate hepatic function (Total bilirubin > . times the institutional upper limit of normal (ULN) (except known Gilbert's syndrome); Alanine transaminase (ALT) or aspartate transaminase (AST) > . times the institutional ULN. ALT or AST up to times the institutional ULN permitted if total bilirubin is normal Alanine aminotransferase (ALT) < . times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < . times ULN is acceptable Hepatic: Bilirubin less than or equal to . times upper limits of normal (ULN), ALT, and aspartate transferase (AST) less than or equal to . times ULN. If the liver has tumor involvement AST and ALT equaling less than or equal to times ULN are acceptable. ALT < times ULN and bilirubin < . mg/dL Serum ALT < . times the ULN. AST, ALT, and alkaline phosphatase (AP) must meet one of the following criteria:\r\n* AST or ALT =< times ULN AND AP =< normal\r\n* AST or ALT =< . times ULN AND AP =< . times ULN\r\n* AST or ALT =< normal AND AP =< times ULN AST or ALT < . times ULN for age Alanine aminotransferase (ALT) < . times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < . times ULN is acceptable; patients with > liver metastases at enrollment will be excluded AST ? . times ULN (? times ULN for patients with liver metastases); Alkaline phosphatase ? . times ULN (? times ULN for patients with liver metastases); Bilirubin ? . mg/dl; AST and ALT < . times the ULN Aspartate aminotransferases (AST) =< times ULN Required prior to infusion of ATLCAR.CD cells: AST =< times ULN Patients with a history of liver disease or AST/ALT >= . times ULN on screening Has laboratory results that are outside of normal limits at screening, as follows: a) Moderate or severe liver dysfunction, as defined as: Aspartate aminotransferase (AST) > times the upper limit of normal (ULN), OR Alanine aminotransferase (ALT) > times the ULN, OR Serum total bilirubin >. times the ULN, OR AST or ALT > times ULN with total bilirubin > times ULN; b) Calculated creatinine clearance < mL/min. Hepatic: bilirubin ?. times upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate transaminase (AST) ?. times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ?. times ULN are acceptable. Alkaline phosphatase ?. times ULN for participants with tumor involvement of the bone is acceptable.